ArticleJHEP reports : innovation in hepatology2025
Incidence and mortality of alcohol-related hepatitis in Denmark - an update, 2016-2023.
Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Low incidence of cytolysin-positiveGut microbes reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Alcohol-related hepatitis (AH) is a severe liver disease associated with high mortality. This study provides data on the incidence and mortality of AH in Denmark from 2016 to 2023. Methods: We identified all patients with a first-time hospital discharge diagnosis of AH and a serum bilirubin level >3 mg/dl in 2016-2023. We computed the standardized incidence rate of AH in the Danish population and mortality from admission with AH. We compared the results to our previously published findings for the 1999-2008 period. Results: We included 1,016 patients with a median age of 54.7 years (66% men). The standardized incidence rate was 21.7 per million per year, which remained stable during the study period for both men and women. Mortality was high: 18% at 28 days, 26% at 84 days, and 40% at 365 days. Although 28-day and 84-day mortality risks were lower in 2023 compared to earlier years, no overall trend of improvement was observed. The median MELD score at admission, available for 846 patients, was consistently high at 26, and 75% had severe AH (MELD >21). Compared to an incidence rate of approximately 45 per million per year in 2009, the incidence of AH has since decreased dramatically, mirroring Danish alcohol sales. Conclusions: The incidence of AH in Denmark markedly declined from 2009 but stabilized between 2016 and 2023. Mortality remains high, emphasizing the need for better treatment strategies. Impact and implications: This study investigated the incidence and mortality of alcohol-related hepatitis (AH) in Denmark from 2016 to 2023, providing updated data in the context of declining alcohol consumption. While AH incidence has decreased since 2009, mirroring reduced alcohol intake, it has stabilized in recent years, and mortality remains high. These findings highlight the ongoing burden of AH for healthcare providers, researchers, and policymakers. Our results can support early interventional strategies, guide clinical management, and reinforce public health efforts to reduce alcohol consumption. Limitations, such as the lack of detailed treatment data, should be considered to avoid overgeneralization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.